Your session is about to expire
← Back to Search
Lenalidomide + Blinatumomab for Lymphoma
Study Summary
This trial is testing the side effects and best dose of lenalidomide and blinatumomab when given together to patients with non-Hodgkin lymphoma that has returned after a period of improvement.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am able to become pregnant, have a negative pregnancy test, and will follow pregnancy precautions.My kidneys work well enough to clear waste from my body.I have undergone at least two different cancer treatments.I finished any previous treatments at least 4 weeks ago.I am HIV positive and meet specific criteria related to my HIV status and treatment.I have an active hepatitis B or C infection.My lymphoma has returned and tests positive for CD19.I haven't had chemotherapy or radiotherapy in the last 4 weeks.I am not using any other cancer treatments.I have taken lenalidomide within the last 8 weeks.I can care for myself but may need occasional help.I have cancer that has spread to my brain.I do not have any unmanaged ongoing illnesses.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Treatment (blinatumomab, lenalidomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What medical conditions is Blinatumomab commonly employed to treat?
"Blinatumomab is typically prescribed as a tertiary treatment step after two other systemic chemotherapy treatments. This medication can also be used for treating amyloidosis, refractory b-cell precursor acute lymphoblastic leukemia, and kidney afflictions."
Has Blinatumomab gained approval from the Food and Drug Administration?
"The safety profile of Blinatumomab was rated a 1, as it is in Phase 1 and there is only limited evidence regarding its efficacy and safety."
What is the current scale of participants in this research project?
"This clinical trial has already reached its recruitment limit, with the most recent edits being made on June 28th 2022. Should you be in search of other studies to participate in, there are currently 2833 trials searching for patients suffering from leukemia and lymphocytic chronic b-cell related illnesses as well as 315 Blinatumomab trials recruiting participants."
Is recruitment still active for this experiment?
"As per the data on clinicaltrials.gov, this particular medical trial is not currently recruiting participants. It was originally posted in June 2016 and last updated two years ago; nonetheless, there are 3148 other trials which are actively seeking patient enrollment presently."
How many venues are hosting this empirical research?
"University of Kansas Cancer Center situated in Kansas City, University of Wisconsin Carbone Cancer Centre located in Duarte, and City of Hope Comprehensive Cancer Centre placed in Birmingham are a few amongst the 10 other medical sites that are running this trial."
What have other scholarly investigations revealed about Blinatumomab?
"Presently, 315 studies utilizing Blinatumomab are in progress. 65 of those trials fall into Phase 3 and the majority of them are based out of Chicago, Illinois. Nevertheless, there are 15607 medical centres running research on this treatment globally."
Share this study with friends
Copy Link
Messenger